Contract Manufacturing

Zenith and SEA Vision partner to offer track-and-trace service

21-Mar-2016 By Dan Stanton

Zenith Technologies and SEA Vision have teamed up to offer drugmakers a service they say will bring “seamless compliance” to upcoming serialisation regulations.

Miltenyi Biotec to help GSK automate R&D cell therapy production

17-Mar-2016 By Staff Reporter

GSK has called on German processing technology firm Miltenyi Biotec to help it automate its cell therapy manufacturing operations.

CORRECTION

Valeant divesting non-core Synergetics CMO business

16-Mar-2016 By Dan Stanton

Valeant is offloading the contract manufacturing business of ophthalmology and neurosurgery medical devices firm Synergetics, acquired last October.

dispatches from DCAT Week '16

AAI and CML rebrand as Alcami

16-Mar-2016 By Melissa Fassbender

AAI Pharma Services (AAI) and Cambridge Major Laboratories (CML) have rebranded as Alcami, a contract development and manufacturing organization. 

TxCell names PCT as Ovasave contract manufacturer in the US

16-Mar-2016 By Gareth Macdonald

TxCell has hired Caladrius Biosciences’ subsidiary PCT as its manufacturer in the US and has started looking for a CMO in Japan.

Amgen selects Patheon as a 'strategic' manufacturing partner

15-Mar-2016 By Dan Stanton

The flexible manufacturing deal with Amgen is a departure from the standard transactional contract approach, according to Patheon.

AAI/CML claims clinical material production time reductions of 65%

14-Mar-2016 By .

AAIPharma and Cambridge Major Labs (CML) under a merged entity have driven efficiencies in end-to-end drug manufacturing, the firm says, dramatically reducing material delivery time.

Purolite targets GE's Protein A resin dominance with plant expansion

11-Mar-2016 By Dan Stanton

Purolite has expanded a facility in Wales to address growing demand for its agarose Protein A resin, used to purify monoclonal antibodies.

Hovione to build US plant for Vertex's cystic fibrosis drugs

10-Mar-2016 By Gareth Macdonald

Hovione and Vertex Pharma have teamed up to set up a continuous manufacturing facility at the former’s site in New Jersey, US.

Peregrine: new biologics plant may boost contracting revenues by $40m

08-Mar-2016 By Gareth Macdonald

Avid Bioservices has formally commissioned a biologics manufacturing facility that more than doubles its production capacity.

Colorcon opens Colombia formulation lab

02-Mar-2016 By Staff Reporter

Colorcon has opened a formulation laboratory in Colombia to build its presence in the fast growing South American pharmaceutical market.

TxCell's CMO completes test batch of candidate Crohn's therapy; contractor training center set up

01-Mar-2016 By Gareth Macdonald

MaSTherCell has completed test runs of T-cell therapy Ovasave says TxCell which has reiterated its intention to restart a trial of the drug in Crohn's disease this year.

Cobra Biologics and UK CPI team on AAV vector production platform

25-Feb-2016 By Gareth Macdonald

Cobra Biologics and the UK Centre for Process Innovation (CPI) will develop a manufacturing system for the viruses used to deliver gene therapies.

Grünenthal formulates deal with Patheon for anti-abuse technology

23-Feb-2016 By Dan Stanton

Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.

Powder study will help safeguard $12bn Danish drug industry, say scientists

22-Feb-2016 By Gareth Macdonald

Research examining how API particle characteristics impact drug stability will help safeguard Denmark’s $12bn (DKK80bn) a year drug manufacturing industry say scientists.

AAI/Cambridge Major Labs to rehouse anaytical services in new MO facility

22-Feb-2016 By Dan Stanton

Increased client demand for analytical testing has driven merged CDMO AAIPharma/Cambridge Major Laboratories to invest $11m into a new facility in Missouri.

ScinoPharm: expanding scope, more products in pipeline, says CEO

22-Feb-2016 By Melissa Fassbender

ScinoPharm Taiwan announced its unaudited financial results for fiscal year 2015, and with it, plans to expand its contract businesses through strategic acquisitions.

MHRA concerned about pharma's preparedness for excipient risk assessments

22-Feb-2016 By Phil Taylor

There are concerns that pharma companies are not fully prepared to meet the new requirements on risk-assessment for excipients, even though the deadline is just a few weeks away.

M&A strategy paying off for AMRI; more API acqs to come

18-Feb-2016 By Dan Stanton

Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.

Symbiosis growing on aseptic demand from US biotech

17-Feb-2016 By Dan Stanton

A robust investment environment and high quality demands have driven US biotech business to UK-based sterile manufacturer Symbiosis, the firm says.

Co-locating trial and commercial manufacturing eases tech transfer and cuts cycle times, Aesica

17-Feb-2016 By Gareth Macdonald

Moving its clinical manufacturing operations to its API and drug site in Queenborough has reduced the risk of problems during tech transfer and cut cycle times according to UK CMO Aesica.

Catalent Q2: Softgel growth blighted by Beinheim plant suspension

10-Feb-2016 By Dan Stanton

Suspension of operations at a French softgel facility reduced Catalent’s second quarter revenues by around $21m, but the firm expects full production to restart in March.

Lonza to make Kodiak Sciences' eye drug candidates

09-Feb-2016 By Gareth Macdonald

Lonza has been contracted to make candidate antibody-based drugs for retinal diseases by California, US biotech Kodiak Sciences.

Juniper to reformulate unpleasant tasting PharmAust cancer drug

08-Feb-2016 By Dan Stanton

Up to 90% of new chemical entities having properties that make them a challenge to successfully formulate, says Juniper Pharmaceuticals which has won a reformulation and manufacturing contract from PharmAust.

Update - facility expansion to continue

Therapure postpones IPO citing market conditions

04-Feb-2016 By Gareth Macdonald

Therapure Biopharma has postponed its IPO citing market conditions.

VC Renaissance: Index Ventures spin off Medicxi launches GSK and J&J backed €210m fund

03-Feb-2016 By Gareth Macdonald

Biologics developers backed by Medicxi Ventures’ new €210m ($229m) fund will use Lonza for contract manufacturing under an existing deal with Index Ventures.

Surging demand for APIs prompts expansion of second Onyx facility

01-Feb-2016 By Dan Stanton

Onyx Scientific will add a 6250sq ft facility at its site in North-East England to cope with a surge in demand for its small-scale API services.

Amatsigroup buys Q Biologicals in 'fragmented' EU bio-services space

27-Jan-2016 By Dan Stanton

French CDMO Amatsigroup will offer complete biologics development services and expand its European presence through the acquisition of Q Biologicals.

Recipharm raises $32m to fund Nitin deal

27-Jan-2016 By Gareth Macdonald

Recipharm has raised SEK276m ($32m) to part finance the acquisition of a majority stake in Indian CMO Nitin Life Sciences that it announced in October.

Hermes adapts food coating technique for API taste masking

26-Jan-2016 By Gareth Macdonald

Hermes Pharma has added hot melt coating capabilities to its offering and hopes the food industry technique will win it pharma customers with unpleasant tasting APIs.

Catalent continues to scout acquisitions and licensing in 2016

25-Jan-2016 By Natalie Morrison

Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.

Catalent bringing clinical supply services to Japanese facility

21-Jan-2016 By Dan Stanton

Catalent will expand its cGMP facility in Japan to bring secondary packaging and clinical supply services to the region.

Johnson Matthey expands Cambridge catalysis facility

21-Jan-2016 By Dan Stanton

Johnson Matthey has expanded its UK biocatalysis R&D operations in response to growing drug industry demand.

Colorcon sweetens its offering with Paulaur's pharma sugar sphere biz

19-Jan-2016 By Dan Stanton

Colorcon has acquired Paulaur Corporation’s sugar sphere business to help feed pharma’s demand for multiparticulate dosage forms.

Vaccine contract manufacturing market to undergo shift, says analyst

12-Jan-2016 By Melissa Fassbender

According to analysts, the vaccine contract manufacturing market is poised for growth, and change, as new players emerge in the East.

AMRI's Burlington to produce cancer drug in JV with Eagle

11-Jan-2016 By Dan Stanton

A chemotherapy drug marketed by Eagle Pharmaceuticals has become the first product approved for commercial manufacture from AMRI’s once troubled Burlington facility.

Paragon launches manufacturing compliance service for drug firms

05-Jan-2016 By Staff writer

Paragon Solutions has rolled out a new service to help drugmakers make sure their manufacturing operations comply with US FDA regulations.

Strategic partnership aligns MG America and COMAS

04-Jan-2016 By Melissa Fassbender

MG America, the US subsidiary of MG2 Bologna, Italy, is expanding its filling division through a recent strategic partnership with COMAS.

Sweden to back biomanufacturing through SEK320m investment scheme

18-Dec-2015 By Gareth Macdonald

The Swedish Government has announced a multi-million kronor plan to back biopharmaceutical research and manufacturing in the country.

Heightened regulatory environment drives AMRI’s $54m Whitehouse acq

17-Dec-2015 By Dan Stanton

AMRI has acquired chemical testing services firm Whitehouse Laboratories to complement its pharma analytical offerings.

Recipharm invests in prostate cancer drug and delivery tech firm LIDDS

17-Dec-2015 By Gareth Macdonald

Recipharm has invested in delivery tech firm and prostate cancer drug developer LIDDS as part of manufacturing contract.

Exec tasked with helping Lonza address "Visp challenge" to step down

14-Dec-2015 By Gareth Macdonald

Beat In-Albon, the man tasked with improving profitability at Lonza’s manufacturing site in Visp, Switzerland, will step down at the end of the year.

Californian SU plant set to go online, but Avid already eying up extra capacity

11-Dec-2015 By Dan Stanton

A new single-use bioproduction plant will bring in annual revenues of $40m, says Avid Bioservices which is already eyeing up additional capacity to cope with contract manufacturing demand.

Reefer Gladness? DEA OKs Catalent to supply marijuana from Missouri plant

09-Dec-2015 By Dan Stanton

Catalent has registered a facility in Missouri with the US DEA to import cannabis extracts in dosage form for clinical trial studies.

Pfizer selects Catalent to make Nexium from expanded Kentucky plant

08-Dec-2015 By Dan Stanton

Catalent will manufacture a heartburn OTC treatment for Pfizer from its newly expanded facility in Kentucky.

Therapure launches IPO to grow biologics contracting business

03-Dec-2015 By Dan Stanton

Therapure Biopharma Inc. plans to go public to fund the expansion of its manufacturing facility and CMO business.

GSK Japan delays alopecia drug launch after Catalent manufacturing halt

03-Dec-2015 By Gareth Macdonald

GSK has delayed the Japanese launch of a male pattern baldness drug after a production halt at a French facility operated by its CMO, Catalent.

Quotient Clinical sold to Dennis Gillings-backed GHO Capital

02-Dec-2015 By Gareth Macdonald

Bridgepoint Capital has sold Quotient Clinical to GHO Capital, a fund backed by Quintiles founder Dennis Gillings.

Tech capabilities to offer CMOs advantages in stable oral dosage sector, report

01-Dec-2015 By Dan Stanton

Niche technologies will differentiate CMOs looking for a slice of the steady oral dosage manufacturing industry, according to an industry report from ISR.

Clariant plans new moisture control tech plant in India

01-Dec-2015 By Gareth Macdonald

Clariant will build a CHF10m ($9.7m) moisture control device plant in Cuddalore, Tamil Nadu to cater for the branded and generic drugmakers operating in India.